| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | For the treatment of unresectable or advanced metastatic melanoma in adults refractory to ipilimumab. |
| Assessment Process | |
| Rapid review commissioned | 06/08/2015 |
| Rapid review completed | 13/08/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 02/11/2015 |
| NCPE assessment completed | 08/02/2016 |
| NCPE assessment outcome | Reimbursement not recommended |
The HSE has approved reimbursement following confidential price negotiations June 2016.
